Urolithin A vs NR (Nicotinamide Riboside): What's the Difference?
Urolithin A and nicotinamide riboside (NR) are two of the most researched compounds in the mitochondrial-health space, and they are often mentioned in the same breath. But they do almost opposite jobs inside the cell, one helps build and fuel mitochondria, the other helps clean them up. Understanding that split is the key to choosing well, or deciding to use both.
The short version
NR is a form of vitamin B3 and a precursor to NAD+, a coenzyme central to energy metabolism. Its aim is to raise NAD+ levels, which support mitochondrial biogenesis (the making of new mitochondria) and many NAD+-dependent enzymes. Urolithin A takes the other side of the cycle: it supports mitophagy, the recycling of worn-out mitochondria. Renewal versus cleanup. That single distinction explains most of the practical differences between them.
What NR (nicotinamide riboside) actually does
Nicotinamide riboside is a vitamin B3 derivative that the body converts into NAD+ (nicotinamide adenine dinucleotide), a coenzyme every cell uses to shuttle energy and to power enzymes such as the sirtuins and PARPs involved in metabolism and DNA repair. NAD+ levels are thought to fall with age, and the logic behind NR is straightforward: supply more of a precursor, and cells can replenish NAD+. Higher NAD+ availability is associated with support for mitochondrial biogenesis, effectively helping cells create new mitochondria and keep energy metabolism running.
The human evidence for the core claim, that NR raises NAD+, is genuinely solid. The first human trial (Trammell et al., 2016, from the University of Iowa) showed a single oral dose raised blood NAD+ safely. A 2018 randomised controlled trial (Martens et al., Nature Communications) found that chronic NR supplementation was well tolerated and reliably elevated NAD+ in healthy middle-aged and older adults. Where the evidence gets thinner is in translating raised NAD+ into clear clinical outcomes: trials examining blood pressure, arterial stiffness, muscle and metabolic endpoints have been mixed or preliminary, and reviewers consistently note that “NAD+ goes up” has been easier to demonstrate than “and here is the downstream benefit.” So NR has strong biomarker evidence and still-developing outcome evidence.
Blood pressure, metabolic and cardiovascular endpoints are condition-adjacent. NR may support NAD+ metabolism, but it is not a treatment for hypertension, metabolic disease or any age-related condition. If you are managing a health issue or take medication, talk to your doctor before starting it. You can also compare NR with the related molecule NMN in our NR overview.
What urolithin A actually does
Urolithin A is a gut postbiotic, a compound your microbiome produces from ellagitannins in pomegranates, walnuts and berries. Only some people convert these precursors efficiently, so taking the finished compound removes that variability. Rather than raising a coenzyme, urolithin A supports mitophagy: the quality-control process that tags damaged mitochondria for recycling so healthier ones can replace them. As mitochondrial quality declines with age, this housekeeping is what urolithin A aims to support. See our complete urolithin A guide and mitochondrial health primer for the full picture.
The human evidence, organised by strength
Established human trials. The first-in-human study (Andreux et al., 2019, Nature Metabolism) found urolithin A safe and well tolerated up to 1,000 mg per day, with a mitochondrial gene-expression signature. A 2022 randomised trial in older adults (Liu, D'Amico et al., JAMA Network Open) reported improved muscle endurance (more contractions before fatigue). A 2022 trial in middle-aged adults (Singh et al., Cell Reports Medicine) tested 500 mg and 1,000 mg and reported gains in muscle strength and exercise performance.
Newer human trials. An 8-week 2024 RCT in resistance-trained men (Journal of the International Society of Sports Nutrition) examined endurance and recovery markers. A 2025 RCT (Nature Aging, ~28 days) found urolithin A supported immune-cell mitochondrial health in midlife adults, and a 2025 distance-runner trial added more exercise data.
Preclinical only. The foundational work (Ryu et al., 2016, Nature Medicine) showed mitophagy, extended lifespan in C. elegans and improved muscle function in rodents. Joint and cartilage work (D'Amico et al., 2022, Aging Cell) used osteoarthritis models. Skin, gut, brain and heart applications remain early, preclinical research. A 2024 systematic review (Ageing Research Reviews) summed up the human evidence as still emerging, from short trials of modest size. Interestingly, both compounds share this pattern: strong mechanistic and biomarker data, with clinical-outcome evidence that is real but still maturing.
Mechanism contrast at a glance
Picture the life cycle of a mitochondrion. NR feeds the front end: by lifting NAD+, it supports the enzymes and signalling (sirtuins, PGC-1α pathways) associated with making new mitochondria and running energy metabolism. Urolithin A works the back end: it supports the removal and recycling of mitochondria that are past their useful life. A cell in good shape needs both to happen, adequate renewal and effective cleanup, which is why these two compounds are often described as addressing complementary halves of mitochondrial turnover rather than competing for the same job. NR raises a coenzyme; urolithin A triggers a housekeeping process. Different levers entirely.
Are they complementary?
Conceptually, yes, and this is the strongest case for pairing in the whole comparison. Because mitochondrial biogenesis (NR's territory) and mitophagy (urolithin A's territory) are two sides of healthy mitochondrial turnover, combining them is a rational strategy that many in the longevity space find appealing. Both have reassuring human safety data at studied doses. What is missing is head-to-head human research showing that the combination outperforms either one alone, so any “1 + 1 = 3” expectation should be held loosely. If you are considering stacking them, it is a reasonable idea in principle, but confirm with your clinician, particularly if you take medications or manage a health condition.
How to choose by goal
Lean toward NR if…
Your interest is specifically NAD+ and the biogenesis side of the equation, and you value that NR has clear, repeated human data showing it raises NAD+. Just keep expectations calibrated: raising the biomarker is well proven; downstream benefits are still being worked out.
Lean toward urolithin A if…
Your priority is muscle strength, endurance and cellular energy with age, where urolithin A has direct human trials on those specific outcomes, and you want the cleanup side of mitochondrial health rather than the raw-material side. Explore urolithin A benefits and compare products in our best urolithin A gummies roundup. If you are also weighing NMN, see our urolithin A vs NMN comparison.
Consider both if…
You want to support both halves of mitochondrial turnover, renewal and recycling, and, after checking with your doctor, are comfortable that combination-specific human evidence is still limited.
Frequently asked questions
Can I take urolithin A and NR together?
Many people do, because they act on complementary halves of mitochondrial turnover, NR on biogenesis via NAD+, urolithin A on mitophagy. Both have reassuring safety data at studied doses. There is not yet head-to-head human research proving the combination beats either alone, so check with your healthcare provider and keep expectations grounded.
What is the main difference between them?
NR is a vitamin B3 precursor that raises NAD+ to support making new mitochondria and energy metabolism. Urolithin A supports mitophagy, the recycling of worn mitochondria. Renewal versus cleanup, two different levers on the same overall system.
Which has stronger human evidence?
It depends on the claim. NR has very strong evidence for one thing, that it raises NAD+. Urolithin A has direct human trials on muscle strength, endurance and exercise performance. Both have clinical-outcome evidence that is still developing, so neither is a clear across-the-board winner.
Does urolithin A raise NAD+?
Raising NAD+ is NR's mechanism, not urolithin A's. Urolithin A works through mitophagy. If your specific goal is NAD+ levels, NR (or NMN) is the compound built for that, whereas urolithin A targets mitochondrial recycling.
What dose of urolithin A is studied?
Human trials used 500 to 1,000 mg per day, with 1,000 mg at the top of the range and shown to be safe and well tolerated. SOMA HEALTH Urolithin A Gummies provide 1,000 mg per 4-gummy daily serving. See our dosage guide.
Are these treatments for aging or disease?
No. Both are studied as supplements that support cellular and mitochondrial health. Neither is intended to diagnose, treat or prevent any disease or to treat aging, and neither replaces a healthy diet, exercise and professional medical care.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This guide is educational and is not a substitute for advice from a qualified healthcare provider.
A clinically studied 1,000 mg dose of Urolithin A in one simple daily gummy — to support mitophagy, muscle strength, and cellular energy.
Shop SOMA Urolithin A Gummies →